Kenan Turnacioglu
Chair of B.O.D at Paige
New York City Metropolitan Area
Overview
Work Experience
Board Member
2022 - Current
Board Member
2020
Member Board Of Directors
2020 - 2022
Board Member
2020 - 2022
Immunai is a biotech company that provides mapping and reprogramming immunology, machine learning, and software engineering.
Raised $295,000,000.00 from Piedmont Capital Investments, Alexandria Venture Investments, Koch Disruptive Technologies, 8VC, ICon, Meron Capital and Talos VC.
Chair Of The Board Of Directors
2017
· Company spun out of Memorial Sloan Kettering with goal of applying machine · Learning/artificial intelligence to supplement the pathologist in diagnosis.
Paige builds software to advance the diagnosis, treatment, and biomarker discovery for cancer.
Raised $220,000,000.00 from Casdin Capital, Catalio Capital Management, Healthcare Venture Partners, Johnson & Johnson Innovation – JJDC and Kohlberg Kravis Roberts.
General Partner & Member of the Investment Committee
2020 - 2021
Catalio Capital Management invests in breakthrough biomedical technologies companies around the globe.
Catalio Capital Management is a venture capital firm that invests in breakthrough biomedical technology companies.
Founding Partner
2011 - 2018
· Founding Partner of Firm that was launched with $4.25bn in assets and grew to $10bn · Managed on average $2bn in capital in Healthcare, Consumer, and TMT · Oversaw the development of the firms Technology and Media group · Oversaw the development of a data science team to analyze large data set · Returns of mid-teens from 2011 to 2017 · Departed firm at end of 2017 to retire from money management business
PointState Capital a hedge fund manger.
Executive Board Member
2013 - 2016
· Company focused on cancer stem cells as targets for antibody therapeutics · Valuation at the time of sale to Abbvie $6.2BN with potential of CVR $4.0BN
Stemcentrx provides pharmaceutical services.
Raised $515,526,990.00 from Sequoia Capital, Artis Ventures (AV), Fidelity, Founders Fund, Silicon Valley Bank and Oakhouse Partners.
Portfolio Manager
2001 - 2010
· Portfolio Manager covering Global Healthcare Industry · Started out as an analyst covering biotech · Portfolio Manager covering Global Healthcare Industry mid-teens returns · Company dissolved in 2010 with the retirement of Founder, Stanley Druckenmiller
Executive Board Member
2004 - 2007
· Company focused on developing antibody therapeutics for cancer targets · Valuation at the time of sale to Astellas was $527mm
Research associate
1999 - 2001
· Research associate covering the biotechnology sector · Initiated on several genomic and antibody companies
Credit Suisse Group is a financial services company that advises clients in all aspects of finance.